BR112017009262A2 - métodos de produção de proteínas de duas cadeias em bactérias - Google Patents
métodos de produção de proteínas de duas cadeias em bactériasInfo
- Publication number
- BR112017009262A2 BR112017009262A2 BR112017009262-0A BR112017009262A BR112017009262A2 BR 112017009262 A2 BR112017009262 A2 BR 112017009262A2 BR 112017009262 A BR112017009262 A BR 112017009262A BR 112017009262 A2 BR112017009262 A2 BR 112017009262A2
- Authority
- BR
- Brazil
- Prior art keywords
- bacteria
- production methods
- protein production
- chain protein
- methods
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000014616 translation Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000040739 Secretory proteins Human genes 0.000 abstract 1
- 108091058545 Secretory proteins Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
a presente invenção refere-se a métodos de produção de um polipeptídeo recombinante que contém duas cadeias, tal como uma proteína de receptor de células t monoclonal mobilizador imunológico contra o câncer (immtac) incluindo uma cadeia alfa e uma cadeia beta. em particular, são proporcionados métodos para a produção de proteínas secretoras heterólogas em bactérias através da utilização de vetores de expressão e processos de cultura otimizados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075798P | 2014-11-05 | 2014-11-05 | |
US62/075,798 | 2014-11-05 | ||
PCT/US2015/059342 WO2016073794A1 (en) | 2014-11-05 | 2015-11-05 | Methods of producing two chain proteins in bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017009262A2 true BR112017009262A2 (pt) | 2018-03-06 |
Family
ID=54602036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017009262-0A BR112017009262A2 (pt) | 2014-11-05 | 2015-11-05 | métodos de produção de proteínas de duas cadeias em bactérias |
Country Status (15)
Country | Link |
---|---|
US (3) | US10066002B2 (pt) |
EP (2) | EP3753948A1 (pt) |
JP (2) | JP6770966B2 (pt) |
KR (1) | KR102544705B1 (pt) |
CN (2) | CN113699203A (pt) |
AU (2) | AU2015342964B2 (pt) |
BR (1) | BR112017009262A2 (pt) |
CA (1) | CA2966573A1 (pt) |
ES (1) | ES2819256T3 (pt) |
HR (1) | HRP20201351T1 (pt) |
IL (2) | IL252028B (pt) |
MX (1) | MX2017005925A (pt) |
RU (2) | RU2739500C2 (pt) |
SI (1) | SI3215525T1 (pt) |
WO (1) | WO2016073794A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170075793A (ko) * | 2014-11-05 | 2017-07-03 | 제넨테크, 인크. | 박테리아 내 2쇄 단백질을 생산하는 방법 |
KR102544705B1 (ko) | 2014-11-05 | 2023-06-15 | 제넨테크, 인크. | 박테리아 내 2쇄 단백질을 생산하는 방법 |
PL3430037T3 (pl) * | 2016-03-16 | 2022-12-19 | Immatics Biotechnologies Gmbh | Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej |
DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
JP7278261B2 (ja) | 2017-08-23 | 2023-05-19 | ノバルティス アーゲー | マルチコピー遺伝子タンパク質発現系 |
AU2019375413A1 (en) * | 2018-11-05 | 2021-05-27 | Genentech, Inc. | Methods of producing two chain proteins in prokaryotic host cells |
CN109371049A (zh) * | 2018-11-14 | 2019-02-22 | 天津大学 | 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用 |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE266710C (pt) | ||||
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
JP2755395B2 (ja) | 1987-09-23 | 1998-05-20 | ブリストル―マイアーズ スクイブ コムパニー | Hiv感染細胞に殺作用する抗体異種結合体 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
AU668423B2 (en) | 1992-08-17 | 1996-05-02 | Genentech Inc. | Bispecific immunoadhesins |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000055183A1 (en) * | 1999-03-17 | 2000-09-21 | Medical Research Council | Method for refolding molecules of polypeptides containing ig domains |
GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
ATE426674T1 (de) * | 2000-11-03 | 2009-04-15 | Genentech Inc | Stoffwechselanderungen in garungen zur produktion rekombinanter proteine |
US6979556B2 (en) * | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
KR100879194B1 (ko) * | 2000-12-14 | 2009-01-16 | 제넨테크, 인크. | 원핵생물에 의해 제조된 항체 및 이의 용도 |
MXPA04001566A (es) | 2001-08-27 | 2004-05-17 | Genentech Inc | Un sistema para expresion y ensamblado de anticuerpos. |
DE60203125T2 (de) * | 2001-08-31 | 2006-04-06 | Avidex Ltd., Abingdon | Löslicher t zell rezeptor |
NZ556507A (en) | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
EP2298810A3 (en) | 2002-07-19 | 2011-08-03 | Abbott Biotechnology Ltd | Treatment of TNF alpha related disorders |
NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
SI1691833T1 (sl) | 2003-11-28 | 2010-06-30 | Micromet Ag | Zmes s polipeptidi |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
SG10201404273QA (en) | 2003-12-23 | 2014-10-30 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
JP4501451B2 (ja) | 2004-02-18 | 2010-07-14 | 株式会社豊田自動織機 | 塗料組成物、塗料組成物を用いた透明性保護膜の製造方法および透明性保護膜を有する有機ガラス |
WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
AU2005282700A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
AU2006342792A1 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
CN101687915B8 (zh) | 2007-04-03 | 2018-08-03 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
KR20170023209A (ko) | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법 |
KR101968766B1 (ko) | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | 이종 폴리펩티드의 분비를 위한 방법 및 조성물 |
TWI586806B (zh) | 2010-04-23 | 2017-06-11 | 建南德克公司 | 異多聚體蛋白質之製造 |
WO2012106615A1 (en) | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
CN104093744A (zh) | 2011-10-11 | 2014-10-08 | 弗·哈夫曼-拉罗切有限公司 | 双特异性抗体的改进的组装 |
US9662450B2 (en) | 2013-03-01 | 2017-05-30 | Sio2 Medical Products, Inc. | Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus |
AR095774A1 (es) | 2013-04-05 | 2015-11-11 | Genentech Inc | Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos |
KR102289258B1 (ko) * | 2013-04-19 | 2021-08-11 | 서트로 바이오파마, 인크. | 상승된 수준의 외인성 샤페론을 갖는 세포 추출물을 이용한 박테리아 세포 비함유 합성 시스템에서의 생물학적 활성 단백질의 발현 |
KR20160124165A (ko) | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | 항-il-13/il-17 이중특이적 항체 및 그의 용도 |
KR102544705B1 (ko) | 2014-11-05 | 2023-06-15 | 제넨테크, 인크. | 박테리아 내 2쇄 단백질을 생산하는 방법 |
KR20170075793A (ko) | 2014-11-05 | 2017-07-03 | 제넨테크, 인크. | 박테리아 내 2쇄 단백질을 생산하는 방법 |
-
2015
- 2015-11-05 KR KR1020177014872A patent/KR102544705B1/ko active IP Right Grant
- 2015-11-05 EP EP20178189.5A patent/EP3753948A1/en active Pending
- 2015-11-05 US US14/934,094 patent/US10066002B2/en active Active
- 2015-11-05 RU RU2017119396A patent/RU2739500C2/ru active
- 2015-11-05 BR BR112017009262-0A patent/BR112017009262A2/pt active Search and Examination
- 2015-11-05 RU RU2020141422A patent/RU2020141422A/ru unknown
- 2015-11-05 CN CN202110839713.7A patent/CN113699203A/zh active Pending
- 2015-11-05 JP JP2017543320A patent/JP6770966B2/ja active Active
- 2015-11-05 WO PCT/US2015/059342 patent/WO2016073794A1/en active Application Filing
- 2015-11-05 ES ES15797531T patent/ES2819256T3/es active Active
- 2015-11-05 AU AU2015342964A patent/AU2015342964B2/en active Active
- 2015-11-05 MX MX2017005925A patent/MX2017005925A/es unknown
- 2015-11-05 CA CA2966573A patent/CA2966573A1/en active Pending
- 2015-11-05 CN CN201580059703.4A patent/CN107075548B/zh active Active
- 2015-11-05 SI SI201531380T patent/SI3215525T1/sl unknown
- 2015-11-05 EP EP15797531.9A patent/EP3215525B1/en active Active
-
2017
- 2017-04-30 IL IL252028A patent/IL252028B/en unknown
-
2018
- 2018-07-25 US US16/045,517 patent/US11091530B2/en active Active
-
2020
- 2020-08-27 HR HRP20201351TT patent/HRP20201351T1/hr unknown
- 2020-09-28 JP JP2020162214A patent/JP6997273B2/ja active Active
-
2021
- 2021-07-06 US US17/368,698 patent/US20220162286A1/en active Pending
- 2021-09-23 AU AU2021236533A patent/AU2021236533B2/en active Active
- 2021-10-18 IL IL287373A patent/IL287373A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017009262A2 (pt) | métodos de produção de proteínas de duas cadeias em bactérias | |
MX2022013540A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
BR112017013981A2 (pt) | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer | |
BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
CO2017001573A2 (es) | Receptor quimérico de antígeno anti-cd123 | |
MX2023011785A (es) | Metodos y composiciones para produccion de proteina de clara de huevo. | |
CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
CO2017001023A2 (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
BR112016029581A2 (pt) | bactéria geneticamente modificada e métodos de modificação genética de bactéria | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
MX2022013454A (es) | Moduladores de la actividad del complemento. | |
BR112016016539A2 (pt) | micro-organismos recombinantes enriquecidos com carboidratos | |
MX2018004121A (es) | Receptores de antigeno y usos de los mismos. | |
CL2016001900A1 (es) | Sobreexpresión de los reguladores de caminos de n-glicosilación para regular la glicosilación de proteinas recombinante | |
EP3448884C0 (en) | MANIPULATED MAMMALIAN CELLS FOR THE PRODUCTION OF RECOMBINANT PROTEINS | |
BR112017020513A2 (pt) | método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe | |
MX2016009084A (es) | Regulacion del metabolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteinas recombinantes. | |
BR112017009152A2 (pt) | métodos de produção de proteínas de duas cadeias em bactérias | |
MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
MY184085A (en) | Method of protein manufacture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |